Wall Street Analyst Downgrade VistaGen Therapeutics Inc. [VTGN]. What else is Wall St. saying

VistaGen Therapeutics Inc. [NASDAQ: VTGN] loss -3.76% or 0.0 points to close at $0.22 with a heavy trading volume of 48995771 shares. The company report on August 11, 2022 that VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Evaluation of PALISADE-1 continues and interim analysis of PALISADE-2 begins.

Preliminary data from nearly 200 subjects in the PALISADE open label safety study suggest that continued as-needed use of PH94B has potential to achieve cumulative functional improvement in the severity of social anxiety disorder (SAD).

It opened the trading session at $0.2281, the shares rose to $0.237 and dropped to $0.19, the range by which the price of stock traded the whole day. The daily chart for VTGN points out that the company has recorded -85.37% loss over the past six months. However, it is still -57.14% lower than its most recent low trading price.

If we look at the average trading volume of 10.65M shares, VTGN reached to a volume of 48995771 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about VistaGen Therapeutics Inc. [VTGN]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VTGN shares is $0.23 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VTGN stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

William Blair have made an estimate for VistaGen Therapeutics Inc. shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on July 22, 2022. The new note on the price target was released on July 22, 2022, representing the official price target for VistaGen Therapeutics Inc. stock.

The Average True Range (ATR) for VistaGen Therapeutics Inc. is set at 0.06, with the Price to Sales ratio for VTGN stock in the period of the last 12 months amounting to 42.00. The Price to Book ratio for the last quarter was 0.98, with the Price to Cash per share for the same quarter was set at 0.24.

Trading performance analysis for VTGN stock

VistaGen Therapeutics Inc. [VTGN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 36.59. With this latest performance, VTGN shares dropped by -79.91% in over the last four-week period, additionally sinking by -85.37% over the last 6 months – not to mention a drop of -91.79% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VTGN stock in for the last two-week period is set at 36.52, with the RSI for the last a single of trading hit 44.35, and the three-weeks RSI is set at 34.52 for VistaGen Therapeutics Inc. [VTGN]. The present Moving Average for the last 50 days of trading for this stock 0.6086, while it was recorded at 0.1892 for the last single week of trading, and 1.3089 for the last 200 days.

VistaGen Therapeutics Inc. [VTGN]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and VistaGen Therapeutics Inc. [VTGN] shares currently have an operating margin of -4308.68 and a Gross Margin at +26.49. VistaGen Therapeutics Inc.’s Net Margin is presently recorded at -4307.19.

Return on Equity for this stock declined to -60.96, with Return on Assets sitting at -52.22.

VistaGen Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.20 and a Current Ratio set at 6.20.

An analysis of insider ownership at VistaGen Therapeutics Inc. [VTGN]

There are presently around $30 million, or 71.40% of VTGN stock, in the hands of institutional investors. The top three institutional holders of VTGN stocks are: VR ADVISER, LLC with ownership of 20,697,286, which is approximately 28.977% of the company’s market cap and around 0.20% of the total institutional ownership; NEA MANAGEMENT COMPANY, LLC, holding 16,302,596 shares of the stock with an approximate value of $3.5 million in VTGN stocks shares; and ORBIMED ADVISORS LLC, currently with $2.89 million in VTGN stock with ownership of nearly 3.966% of the company’s market capitalization.

Positions in VistaGen Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 54 institutional holders increased their position in VistaGen Therapeutics Inc. [NASDAQ:VTGN] by around 15,604,924 shares. Additionally, 57 investors decreased positions by around 10,728,297 shares, while 22 investors held positions by with 112,479,885 shares. The mentioned changes placed institutional holdings at 138,813,106 shares, according to the latest SEC report filing. VTGN stock had 21 new institutional investments in for a total of 5,364,747 shares, while 21 institutional investors sold positions of 5,165,656 shares during the same period.


Please enter your comment!
Please enter your name here